You are here

Advanced glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study.

TitleAdvanced glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study.
Publication TypeJournal Article
Year of Publication2019
AuthorsGarg, PK, Biggs, ML, Barzilay, J, Djoussé, L, Hirsch, C, Ix, JH, Kizer, JR, Tracy, RP, Newman, AB, Siscovick, DS, Mukamal, KJ
JournalDiab Vasc Dis Res
Pagination1479164119847481
Date Published2019 May 08
ISSN1752-8984
Abstract<p>Carboxymethyl-lysine is an advanced glycation end product that is detectable in the serum. Higher carboxymethyl-lysine levels have been associated with increased risk of coronary heart disease, stroke and cardiovascular mortality. We determined whether high carboxymethyl-lysine levels are also associated with the risk of peripheral artery disease in Cardiovascular Health Study participants who were all aged 65 years and older at baseline. Multivariate Cox proportional hazards models were used to determine the association of baseline carboxymethyl-lysine levels with incident peripheral artery disease in 3267 individuals followed for a median length of 10.0 years. A total of 157 cases of incident peripheral artery disease occurred during follow-up. No significant relationship between carboxymethyl-lysine and risk of peripheral artery disease was found (hazard ratio per standard deviation increment = 1.03; 95% confidence interval = 0.87, 1.23).</p>
DOI10.1177/1479164119847481
Alternate JournalDiab Vasc Dis Res
PubMed ID31064218
ePub date: 
19/05